skip to Main Content

Circulating Nucleic Acids are Associated with Outcomes of Patients with Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
In 37 disease control individuals and 194 patients undergoing treatment for localized or metastatic pancreatic adenocarcinoma from April 7, 2015, through October 13, 2017, researchers studied the clinical utility of circulating tumor cell DNA (ctDNA) and exosome DNA (exoDNA).

The concordance rate of KRAS mutations in surgically resected tissue detected in liquid biopsy samples was more than 95%. Longitudinal monitoring of exoDNA provides unique predictive information on the outcome of neoadjuvant therapy in localized disease and in anticipating progression in the metastatic setting although the baseline CA19-9, exoDNA, and ctDNA cargo have a prognostic effect. Read more . . . 

Back To Top